Pharmacogenetics of cancer drugs

Annual Review of Medicine

Volumn 66, Issue , 2015, Pages 65-81

  Hertz, Daniel L ^a   Rae, James ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

germline genome; single nucleotide polymorphism

Indexed keywords

ANTINEOPLASTIC AGENT; AZATHIOPRINE; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYTOCHROME P450 2D6; DRUG METABOLIZING ENZYME; ENDOXIFEN; FIRTECAN; FLUOROURACIL; GLUCURONOSYLTRANSFERASE 1A1; HLA DQA1 ANTIGEN; HLA DRB1 ANTIGEN; IRINOTECAN; LAPATINIB; LETROZOLE; MERCAPTOPURINE; METHOTREXATE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NILOTINIB; OLAPARIB; OXALIPLATIN; PAZOPANIB; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; SUNITINIB; TAMOXIFEN; THIOPURINE METHYLTRANSFERASE; TIOGUANINE; UNINDEXED DRUG;

ANTIGEN PRESENTATION; ARTICLE; BONE MARROW TOXICITY; CANCER PATIENT; CANCER RESISTANCE; CANCER THERAPY; CONSENSUS; CYTOTOXICITY; DNA REPAIR; DNA STRAND BREAKAGE; DNA SYNTHESIS; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; DRUG SENSITIVITY; ENZYME ACTIVITY; EXCISION REPAIR; EXOME; GASTROINTESTINAL TOXICITY; GENE DUPLICATION; GENE EXPRESSION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; GERMLINE MUTATION; HLA SYSTEM; HOMOZYGOTE; HUMAN; HYPERBILIRUBINEMIA; LIVER FUNCTION; LIVER INJURY; LIVER TOXICITY; MEDICAL DECISION MAKING; MYOPATHY; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; ONCOGENE; OTOTOXICITY; PHARMACOGENETICS; PHARMACOGENOMICS; PHENOTYPE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE; URINARY EXCRETION; ADVERSE DRUG REACTION; GENETICS; NEOPLASMS;

ANTINEOPLASTIC AGENTS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; NEOPLASMS; PHARMACOGENETICS; TREATMENT OUTCOME;

EID: 84921417445     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-053013-053944     Document Type: Article

References (99)

1. Kandoth C, McLellan MD, Vandin F, et al. 2013. Mutational landscape and significance across 12 major cancer types. Nature 502:333-39
2. Chmielecki J, Meyerson M. 2014. DNA sequencing of cancer: What have we learned?. Annu. Rev. Med. 65:63-79
3. Hertz DL, McLeod HL. 2013. Use of pharmacogenetics for predicting cancer prognosis and treatment exposure, response and toxicity. J. Hum. Genet. 58:346-52
4. McLeod HL, EvansWE.2001. Pharmacogenomics: unlocking the human genome for better drug therapy. Annu. Rev. Pharmacol. Toxicol. 41:101-21
5. Daly AK. 2012. Using genome-wide association studies to identify genes important in serious adverse drug reactions. Annu. Rev. Pharmacol. Toxicol. 52:21-35
6. Martin MA, Kroetz DL. 2013. Abacavir pharmacogenetics-from initial reports to standard of care. Pharmacotherapy 33:765-75
7. Hertz DL, McLeod HL. 2014. Using pharmacogene polymorphism panels to detect germline pharmacodynamic markers in oncology. Clin. Cancer Res. 20:2530-40
8. Crews KR, Hicks JK, Pui CH, et al. 2012. Pharmacogenomics and individualized medicine: translating science into practice. Clin. Pharmacol. Ther. 92:467-75
9. Teutsch SM, Bradley LA, Palomaki GE, et al. 2009. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP working group. Genet. Med. 11:3-14
10. Hall JM, Friedman L, Guenther C, et al. 1992. Closing in on a breast cancer gene on chromosome 17q. Am. J. Hum. Genet. 50:1235-42
11. Brugarolas J, Jacks T. 1997. Double indemnity: p53, BRCA and cancer. Nat. Med. 3:721-22
12. Poklar N, Pilch DS, Lippard SJ, et al. 1996. Influence of cisplatin intrastrand crosslinking on the conformation, thermal stability, and energetics of a 20-mer DNA duplex. Proc. Natl. Acad. Sci. USA 93:7606-11
13. Cass I, Baldwin RL, Varkey T, et al. 2003. Improved survival in women with BRCA-Associated ovarian carcinoma. Cancer 97:2187-95
14. AlsopK, Fereday S, MeldrumC, et al. 2012. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian ovarian cancer study group. J. Clin. Oncol. 30:2654-63
15. Farmer H, McCabe N, Lord CJ, et al. 2005. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434:917-21
16. Bryant HE, Schultz N, Thomas HD, et al. 2005. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434:913-17
17. AudehMW, Carmichael J, Penson RT, et al. 2010. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 376:245-51
18. Kaye SB, Lubinski J, Matulonis U, et al. 2012. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J. Clin. Oncol. 30:372-79
19. Hennessy BT, Timms KM, Carey MS, et al. 2010. Somaticmutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J. Clin. Oncol. 28:3570-6
20. A2014. Positive results for drug combo in I-SPY 2 trial. Cancer Discov. 4:OF2
21. Pavlos R, Mallal S, Phillips E. 2012. HLA and pharmacogenetics of drug hypersensitivity. Pharmacogenomics 13:1285-306
22. Spraggs CF, Budde LR, Briley LP, et al. 2011. HLA-DQA102:01 is a major risk factor for lapatinibinduced hepatotoxicity in women with advanced breast cancer. J. Clin. Oncol. 29:667-73
23. Schaid DJ, Spraggs CF, McDonnell SK, et al. 2014. Prospective validation of HLA-DRB107:01 allele carriage as a predictive risk factor for lapatinib-induced liver injury. J. Clin. Oncol. 32:2296-303
24. Krynetski EY, Schuetz JD, Galpin AJ, et al. 1995. A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc. Natl. Acad. Sci. USA 92:949-53
25. Tai HL, Krynetski EY, Schuetz EG, et al. 1997. Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT3A, TPMT2): mechanisms for the genetic polymorphism of TPMT activity. Proc. Natl. Acad. Sci. USA 94:6444-49
26. Otterness DM, Szumlanski CL, Wood TC, Weinshilboum RM. 1998. Human thiopurine methyltransferase pharmacogenetics. Kindred with a terminal exon splice junction mutation that results in loss of activity. J. Clin. Investig. 101:1036-44
27. RellingMV, HancockML, RiveraGK, et al. 1999. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J. Natl. Cancer Inst. 91:2001-8
28. Lennard L, Lilleyman JS, Van Loon J, Weinshilboum RM. 1990. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 336:225-29
29. Black AJ, McLeod HL, Capell HA, et al. 1998. Thiopurine methyltransferase genotype predicts therapylimiting severe toxicity from azathioprine. Ann. Intern. Med. 129:716-18
30. Stanulla M, Schaeffeler E, Flohr T, et al. 2005. Thiopurinemethyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. JAMA 293:1485-89
31. Schmiegelow K, Forestier E, Hellebostad M, et al. 2010. Long-Term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia. Leukemia 24:345-54
32. Levinsen M, Rotevatn EO, Rosthoj S, et al. 2014. Pharmacogenetically based dosing of thiopurines in childhood acute lymphoblastic leukemia: influence on cure rates and risk of second cancer. Pediatr. Blood Cancer 61:797-802
33. Yates CR, Krynetski EY, Loennechen T, et al. 1997. Molecular diagnosis of thiopurine Smethyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann. Intern. Med. 126:608-14
34. Hindorf U, Appell ML. 2012. Genotyping should be considered the primary choice for pre-Treatment evaluation of thiopurine methyltransferase function. J. Crohn's Colitis 6:655-59
35. van den Akker-van Marle ME, Gurwitz D, Detmar SB, et al. 2006. Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurinemethyltransferase genotyping in acute lymphoblastic leukemia in Europe. Pharmacogenomics 7:783-92
36. Bell GC, Crews KR, Wilkinson MR, et al. 2014. Development and use of active clinical decision support for preemptive pharmacogenomics. J. Am. Med. Inform. Assoc. 21:e93-99
37. Relling MV, Klein TE. 2011. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin. Pharmacol. Ther. 89:464-67
38. Relling MV, Gardner EE, Sandborn WJ, et al. 2013. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update. Clin. Pharmacol. Ther. 93:324-25
39. Travis LB, Fossa SD, Sesso HD, et al. 2014. Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics. J. Natl. Cancer Inst. In press
40. Ross CJ, Katzov-Eckert H, Dube MP, et al. 2009. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat. Genet. 41:1345-49
41. Pussegoda K, Ross CJ, Visscher H, et al. 2013. Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children. Clin. Pharmacol. Ther. 94:243-51
42. Yang JJ, Lim JY, Huang J, et al. 2013. The role of inherited TPMT and COMT genetic variation in cisplatin-induced ototoxicity in children with cancer. Clin. Pharmacol. Ther. 94:252-59
43. Khrunin AV, Khokhrin DV, Moisseev AA, et al. 2014. Pharmacogenomic assessment of cisplatin-based chemotherapy outcomes in ovarian cancer. Pharmacogenomics 15:329-37
44. Diasio RB, Beavers TL, Carpenter JT. 1988. Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J. Clin. Investig. 81:47-51
45. Teh LK, Hamzah S, Hashim H, et al. 2013. Potential of dihydropyrimidine dehydrogenase genotypes in personalizing 5-fluorouracil therapy among colorectal cancer patients. Ther. Drug Monit. 35:624-30
46. Morel A, Boisdron-Celle M, Fey L, et al. 2006. Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance. Mol. Cancer Ther. 5:2895-904
47. Boisdron-Celle M, Remaud G, Traore S, et al. 2007. 5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency. Cancer Lett. 249:271-82
48. Schwab M, Zanger UM, Marx C, et al. 2008. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J. Clin. Oncol. 26:2131-38
49. Terrazzino S, Cargnin S, Del ReM, et al. 2013. DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-Analysis. Pharmacogenomics 14:1255-72
50. Magnani E, Farnetti E, Nicoli D, et al. 2013. Fluoropyrimidine toxicity in patientswith dihydropyrimidine dehydrogenase splice site variant: the need for further revision of dose and schedule. Intern. Emerg. Med. 8:417-23
51. Deenen MJ, Cats A, Sechterberger MK, et al. 2011. Safety, pharmacokinetics (PK), and cost-effectiveness of upfront genotyping of DPYD in fluoropyrimidine therapy. ASCO Meet. Abstr. 29:3606
52. Caudle KE, Thorn CF, Klein TE, et al. 2013. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Clin. Pharmacol. Ther. 94:640-45
53. Bosma PJ, Seppen J, Goldhoorn B, et al. 1994. Bilirubin UDP-glucuronosyltransferase 1 is the only relevant bilirubin glucuronidating isoform in man. J. Biol. Chem. 269:17960-64
54. Bosma PJ, Chowdhury JR, Bakker C, et al. 1995. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N. Engl. J. Med. 333:1171-75
55. Toffoli G, Cecchin E, Corona G, et al. 2006. The role of UGT1A128 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J. Clin. Oncol. 24:3061-68
56. Ando Y, Saka H, Asai G, et al. 1998. UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan. Ann. Oncol. 9:845-47
57. Hoskins JM, Goldberg RM, Qu P, et al. 2007. UGT1A128 genotype and irinotecan-induced neutropenia: dose matters. J. Natl. Cancer Inst. 99:1290-95
58. Dias MM, McKinnon RA, Sorich MJ. 2012. Impact of the UGT1A128 allele on response to irinotecan: a systematic review and meta-Analysis. Pharmacogenomics 13:889-99
59. Liu X, Cheng D, Kuang Q, et al. 2013. Association between UGT1A128 polymorphisms and clinical outcomes of irinotecan-based chemotherapies in colorectal cancer: a meta-Analysis in Caucasians. PLOS ONE 8:e58489
60. Marcuello E, Paez D, Pare L, et al. 2011. A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer. Br. J. Cancer 105:53-57
61. Toffoli G, Cecchin E, Gasparini G, et al. 2010. Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer. J. Clin. Oncol. 28:866-71
62. Hazama S, Nagashima A, KondoH, et al. 2010. Phase I study of irinotecan and doxifluridine for metastatic colorectal cancer focusing on the UGT1A128 polymorphism. Cancer Sci. 101:722-27
63. Okuyama Y, Hazama S, Nozawa H, et al. 2011. Prospective phase II study of FOLFIRI for mCRC in Japan, including the analysis of UGT1A128/6 polymorphisms. Jpn. J. Clin. Oncol. 41:477-82
64. Swen JJ, Nijenhuis M, de Boer A, et al. 2011. Pharmacogenetics: from bench to byte-An update of guidelines. Clin. Pharmacol. Ther. 89:662-73
65. Shibata T, Minami Y, MitsumaA, et al. 2013. Association between severe toxicity of nilotinib andUGT1A1 polymorphisms in Japanese patients with chronic myelogenous leukemia. Int. J. Clin. Oncol. 19:391-96
66. Singer JB, Shou Y, Giles F, et al. 2007. UGT1A1 promoter polymorphism increases risk of nilotinibinduced hyperbilirubinemia. Leukemia 21:2311-15
67. Xu CF, Reck BH, Xue Z, et al. 2010. Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism. Br. J. Cancer 102:1371-77
68. Motzer RJ, Johnson T, Choueiri TK, et al. 2013. Hyperbilirubinemia in pazopanib-or sunitinib-Treated patients in COMPARZ is associated with UGT1A1 polymorphisms. Ann. Oncol. 24:2927-28
69. Fujita KI, Sugiyama M, Akiyama Y, et al. 2011. The small-molecule tyrosine kinase inhibitor nilotinib is a potent noncompetitive inhibitor of the SN-38 glucuronidation by human UGT1A1. Cancer Chemother. Pharmacol. 67:237-41
70. SEARCH Collab. Group. 2008. SLCO1B1 variants and statin-induced myopathy-A genomewide study. N. Engl. J. Med. 359:789-99
71. Wilke RA, Ramsey LB, Johnson SG, et al. 2012. The Clinical Pharmacogenomics Implementation Consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin. Pharmacol. Ther. 92:112-17
72. Rohrbacher M, Kirchhof A, Skarke C, et al. 2006. Rapid identification of three functionally relevant polymorphisms in the OATP1B1 transporter gene using PyrosequencingTM. Pharmacogenomics 7:167-76
73. van de Steeg E, van der Kruijssen CMM, Wagenaar E, et al. 2009. Methotrexate pharmacokinetics in transgenic mice with liver-specific expression of human organic anion-Transporting polypeptide 1B1 (SLCO1B1). Drug Metab. Dispos. 37:277-81
74. Trevĩno LR, Shimasaki N, Yang W, et al. 2009. Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J. Clin. Oncol. 27:5972-78
75. Ramsey LB, Panetta JC, Smith C, et al. 2013. Genome-wide study of methotrexate clearance replicates SLCO1B1. Blood 121:898-904
76. RamseyLB, BruunGH, YangW, et al. 2012. Rare versus commonvariants in pharmacogenetics:SLCO1B1 variation and methotrexate disposition. Genome Res. 22:1-8
77. Radtke S, Zolk O, Renner B, et al. 2013. Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia. Blood 121:5145-53
78. Crews KR, Gaedigk A, DunnenbergerHM, et al. 2012. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin. Pharmacol. Ther. 91:321-26
79. Borges S, Desta Z, Jin Y, et al. 2010. Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients. J. Clin. Pharmacol. 50:450-58
80. Teft WA, Gong IY, Dingle B, et al. 2013. CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy. Breast Cancer Res. Treat. 139:95-105
81. Madlensky L, Natarajan L, Tchu S, et al. 2011. Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin. Pharmacol. Ther. 89:718-25
82. LorizioW, WuAB, BeattieM, et al. 2012. Clinical and biomarker predictors of side effects from tamoxifen. Breast Cancer Res. Treat. 132:1107-18
83. Hertz DL, McLeod HL, Irvin WJ. 2012. Tamoxifen and CYP2D6: a contradiction of data. Oncologist 17:620-30
84. Regan MM, Leyland-Jones B, Bouzyk M, et al. 2012. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. J. Natl. Cancer Inst. 104:441-51
85. Rae JM, Drury S, Hayes DF, et al. 2012. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-Treated breast cancer patients. J. Natl. Cancer Inst. 104:452-60
86. Irvin WJ Jr, Walko CM, Weck KE, et al. 2011. Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study. J. Clin. Oncol. 29:3232-39
87. ToyW, Shen Y, Won H, et al. 2013. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat. Genet. 45:1439-45
88. Robinson DR, Wu YM, Vats P, et al. 2013. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat. Genet. 45:1446-51
89. Ioannidis JP, Tarone R, McLaughlin JK. 2011. The false-positive to false-negative ratio in epidemiologic studies. Epidemiology 22:450-56
90. Green ED, Guyer MS, Natl. Hum. Genome Res. Inst. 2011. Charting a course for genomic medicine from base pairs to bedside. Nature 470:204-13
91. Relling MV, Altman RB, Goetz MP, Evans WE. 2010. Clinical implementation of pharmacogenomics: overcoming genetic exceptionalism. Lancet Oncol. 11:507-9
92. Kimmel SE, French B, Kasner SE, et al. 2013. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N. Engl. J. Med. 369:2283-93
93. Altman RB. 2011. Pharmacogenomics: 'Noninferiority' is sufficient for initial implementation. Clin. Pharmacol. Ther. 89:348-50
94. Relling MV, Klein TE. 2011. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin. Pharmacol. Ther. 89:464-67
95. Roychowdhury S, Iyer MK, Robinson DR, et al. 2011. Personalized oncology through integrative highthroughput sequencing: a pilot study. Sci. Transl. Med. 3:111ra121
96. Richter S, Haroun I, Graham TC, et al. 2013. Variants of unknown significance in BRCA testing: impact on risk perception, worry, prevention and counseling. Ann. Oncol. 24(Suppl 8):viii69-74
97. Ashley EA, Butte AJ, Wheeler MT, et al. 2010. Clinical assessment incorporating a personal genome. Lancet 375:1525-35
98. Rae JM, Regan MM, Thibert JN, et al. 2013. Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA. J. Natl. Cancer Inst. 105:1332-34
99. Nakamura Y, Ratain MJ, Cox NJ, et al. 2012. Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. J. Natl. Cancer Inst. 104:1264; author reply 1266-68